Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Executive Summary
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.